Trevena (NASDAQ:TRVN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a research report released on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $5.00 price target on shares of Trevena in a research note on Thursday, November 14th.

Trevena Price Performance

Shares of TRVN opened at $1.63 on Thursday. Trevena has a 1-year low of $1.13 and a 1-year high of $19.23. The company has a market capitalization of $1.40 million, a P/E ratio of -0.03 and a beta of 1.08. The firm’s 50 day simple moving average is $2.05 and its 200 day simple moving average is $4.70.

Trevena (NASDAQ:TRVN) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The firm had revenue of $0.28 million for the quarter. On average, equities analysts anticipate that Trevena will post -23.04 earnings per share for the current year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.